by Ethan Perlstein | Mar 13, 2018 | Business |
Economies of scale are the efficiencies unlocked by large numbers. I’ve come to realize that the efficiencies of scale can emerge at the opposite extreme of rare – especially ultra-rare – genetic disease communities, which can number as few as dozens to thousands of...
by Sangeetha Iyer | Feb 20, 2018 | PMM2-CDG |
Perlara and Maggie’s Cure have started a PerlQuest for a glycosylation disorder called PMM-2 deficiency disease – one of the most common congenital disorders of glycosylation. Over the past year at Perlara, we have modeled the pmm-2 deficiency disorder in yeast,...
by Sangeetha Iyer | Feb 6, 2018 | Niemann-Pick Type A |
In December of 2016, Perlara partnered with Wylder Nation to initiate an NPA PerlQuest, a research and drug discovery program for Niemann Pick Type A disease. If you’ve been following our blog, you’ve kept up with our fly team’s efforts in...
by Jessica Lao | Jan 29, 2018 | PMM2-CDG |
A goal of Stage 1 of our PMM2-CDG PerlQuest with Maggie’s Cure is to identify yeast models that are suitable for use in screens for small molecules that rescue PMM2 deficiency. As described below, we successfully developed screen-ready yeast models that mirror two...
by Tamy Portillo Rodriguez | Nov 1, 2017 | Perlara science |
Perlara’s high throughput screen progress in Mucolipidosis IV (MLIV) flies… In this blog post, I’ll tell you about Perlara’s high throughput screen progress in MLIV flies. Last year, Tom Hartl reviewed some details of MLIV disease biology and described how...
